Artelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd

LA JOLLA, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas, Chief Executive Officer of Artelo Biosciences, will be presenting at the Q1 Virtual Investor Summit.

About The Investor Summit

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors.

To request complimentary investor registration: please visit our website at www.investorsummitgroup.com

About Artelo Biosciences

Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting lipid-signaling pathways, including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at

www.artelobio.com and Twitter: @ArteloBio.

Investor Relations Contact:

Crescendo Communications, LLC

Email: ARTL@crescendo-ir.com

Investor Summit Contact:

Brittney Blocker at brittney@investorsummitgroup.com

Wire Service Contact

Los Angeles, California

Q1 Virtual Investor Summit

lipid-signaling pathways